Dovitinib (TKI258), a small-molecule inhibitor of FGFR1, FGFR2, and FGFR3 and other receptor tyrosine kinases [36], has shown preclinical activity in FGFR-expressing breast cancer models in vivo and in vitro [37]. Here, FGFR2 is linked to breast carcinoma.